Tissue Regenix Secures Key Certifications for OrthoPure® XT, Boosting Market Expansion

Tissue Regenix ( (GB:TRX) ) has shared an update.

Tissue Regenix has secured CE and UKCA certifications for its OrthoPure® XT tendon replacement technology, ensuring compliance with the latest EU and UK medical device regulations. This achievement allows the company to maintain access to the European medical device market, supporting revenue growth and international expansion. The certifications also enhance the product’s marketability by extending its shelf life and facilitating new business opportunities. OrthoPure® XT, utilizing the company’s dCELL® technology, is a unique non-human biologic graft for knee ligament reconstruction, reinforcing Tissue Regenix’s commitment to quality and safety.

More about Tissue Regenix

Tissue Regenix is a leading medical device company specializing in regenerative medicine. The company utilizes its patented decellularisation technology, dCELL®, to create acellular tissue scaffolds for repairing damaged body structures. Their products cater to clinical needs in sports medicine, foot and ankle injuries, and wound care. Tissue Regenix expanded its capabilities by acquiring CellRight Technologies, which focuses on regenerative tissue scaffolds for various surgical procedures.

Average Trading Volume: 29,244

Technical Sentiment Signal: Sell

Current Market Cap: £22.08M

Find detailed analytics on TRX stock on TipRanks’ Stock Analysis page.